Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are establishing a standardized clinical database for patients with liver cancer, including hepatocellular carcinoma and related types, to support high-quality real-world clinical studies. This observational study is led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China USTC in collaboration with multiple centers nationwide. The purpose is to collect detailed clinical information to better understand liver cancer outcomes over time. Participants will receive routine clinical treatments for liver cancer, such as surgical resection, ablation, transarterial chemoembolization TACE, hepatic arterial infusion chemotherapy HAIC, and various anti-tumor drugs including immunologic, targeted, and chemotherapy agents. The study observes and records these standard treatments without assigning interventions. The research will track these patients in a cohort database to monitor their treatment and progression. During the study, participants will be followed for up to 10 years to assess overall survival, recurrence-free survival, and survival time after cancer recurrence. Researchers will collect blood and surgical tissue samples and perform regular follow-up visits to gather clinical data and pathology results. This long-term monitoring aims to provide comprehensive insights into liver cancer progression and treatment outcomes.
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of combining an interleukin-6 inhibitor called tocilizumab with endovascular therapy in adults who have experienced an acute posterior circulation large-vessel occlusion stroke. This phase III clinical trial aims to see if adding tocilizumab can improve recovery outcomes for these patients. The trial is randomized, double-blind, and placebo-controlled, ensuring a rigorous comparison between treatments. Participants will receive either endovascular treatment combined with a single intravenous infusion of 240 mg tocilizumab or endovascular treatment combined with a placebo infusion. The infusion will be given immediately after randomization within 30 minutes and will take more than one hour to complete. This study involves two groups running in parallel to compare the effects of tocilizumab against placebo. During the study, participants will be assessed on their recovery using the modified Rankin Scale at 90 days as the main measure. Additional assessments include neurological improvement shortly after treatment, stroke severity scores at 7 days, and quality of life evaluations up to one year. Safety and functional outcomes will be closely monitored through various scales and indexes, with the total follow-up lasting up to one year after treatment.